Table 2. Association of baseline characteristics and regdanvimab treatment on disease progression in patients with COVID-19.
| Variables | Pre-matched cohort (n = 507) | Propensity score-matched cohort (n = 344) | |||
|---|---|---|---|---|---|
| Unadjusted OR (95% CI) | Adjusted OR (95% CI) | Unadjusted OR (95% CI) | Adjusted OR (95% CI) | ||
| Age, ≥65 years | 1.872 (0.970 – 3.611) | 1.722 (0.840 – 3.532) | 1.635 (0.746 – 3.583) | ||
| Male | 0.686 (0.380 – 1.239) | 0.734 (0.369 – 1.460) | |||
| Diabetes | 1.116 (0.617 – 2.021) | 1.708 (0.868 – 3.361) | |||
| Hypertension | 2.464 (1.297 – 4.681) | 2.766 (1.388 – 5.509) | 3.395 (1.555 – 7.412) | 3.170 (1.379 – 7.286) | |
| Coronary artery disease | 0.839 (0.288 – 2.443) | 0.789 (0.229 – 2.719) | |||
| Chronic lung disease | 0.487 (0.064 – 3.723) | ||||
| Cerebrovascular disease | 1.167 (0.395 – 3.450) | 1.007 (0.288 – 3.517) | |||
| BMI ≥30 kg/m2 | 0.890 (0.202 – 3.922) | 1.833 (0.381 – 8.819) | |||
| Fever ≥38°C on admission | 2.654 (1.391 – 5.063) | 1.929 (0.874 – 4.257) | 2.955 (1.318 – 6.624) | 2.144 (0.824 – 5.578) | |
| C- reactive protein ≥1 mg/dL | 3.977 (2.186 – 7.234) | 3.572 (1.836 – 6.951) | 3.655 (1.829 – 7.304) | 3.950 (1.838 – 8.489) | |
| WBCs >10 × 103/mm3 | 1.030 (0.126 – 8.407) | 1.926 (0.210 – 17.693) | |||
| Platelet <150 × 103/mm3 | 2.781 (1.466 – 5.275) | 2.322 (1.141 – 4.727) | 2.269 (1.049 – 4.905) | 1.702 (0.688 – 4.214) | |
| COVID-19 vaccination | 1.014 (0.522 – 1.971) | 0.673 (0.314 – 1.443) | 1.132 (0.537 – 2.385) | 0.753 (0.314 – 1.806) | |
| Two doses of vaccination | 0.649 (0.150 – 2.810) | 1.078 (0.237 – 4.906) | |||
| Moderate severity vs. No symptom to mild | 3.045 (1.622 – 5.717) | 3.049 (1.489 – 6.244) | 2.310 (1.139 – 4.685) | 2.167 (0.996 – 4.717) | |
| Regdanvimab treatment | 0.601 (0.333 – 1.086) | 0.285 (0.144 – 0.564) | 0.231 (0.103 – 0.520) | 0.162 (0.068 – 0.386) | |
COVID-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval; BMI, body mass index; WBC, white blood cell.